Geode Capital Management’s Moleculin Biotech MBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $132K | Buy |
2,363
+747
| +46% | +$38.1K | ﹤0.01% | 4039 |
|
|
2026
Q1 | $74K | Buy |
1,616
+859
| +113% | +$56.8K | ﹤0.01% | 4214 |
|
|
2025
Q4 | $50.1K | Buy |
757
+341
| +82% | +$63.5K | ﹤0.01% | 4231 |
|
|
2025
Q3 | $110K | Buy |
416
+361
| +656% | +$97.5K | ﹤0.01% | 4105 |
|
|
2025
Q2 | $8.31K | Buy |
55
+3
| +6% | +$1.23K | ﹤0.01% | 4423 |
|
|
2025
Q1 | $25.4K | Buy |
52
+8
| +18% | +$5.38K | ﹤0.01% | 4307 |
|
|
2024
Q4 | $37.5K | Hold |
44
| – | – | ﹤0.01% | 4287 |
|
|
2024
Q3 | $62K | Buy |
44
+4
| +10% | +$5.76K | ﹤0.01% | 4220 |
|
|
2024
Q2 | $69K | Buy |
40
+7
| +21% | +$16.2K | ﹤0.01% | 4218 |
|
|
2024
Q1 | $98.2K | Hold |
33
| – | – | ﹤0.01% | 4163 |
|
|
2023
Q4 | $212K | Hold |
33
| – | – | ﹤0.01% | 3922 |
|
|
2023
Q3 | $105K | Hold |
33
| – | – | ﹤0.01% | 4232 |
|
|
2023
Q2 | $143K | Hold |
33
| – | – | ﹤0.01% | 4197 |
|
|
2023
Q1 | $237K | Hold |
33
| – | – | ﹤0.01% | 3957 |
|
|
2022
Q4 | $261K | Hold |
33
| – | – | ﹤0.01% | 3949 |
|
|
2022
Q3 | $261K | Hold |
33
| – | – | ﹤0.01% | 4051 |
|
|
2022
Q2 | $358K | Hold |
33
| – | – | ﹤0.01% | 3942 |
|
|
2022
Q1 | $437K | Hold |
33
| – | – | ﹤0.01% | 4004 |
|
|
2021
Q4 | $456K | Hold |
33
| – | – | ﹤0.01% | 4105 |
|
|
2021
Q3 | $736K | Buy |
33
+1
| +3% | +$23.4K | ﹤0.01% | 3839 |
|
|
2021
Q2 | $871K | Buy |
32
+9
| +39% | +$246K | ﹤0.01% | 3679 |
|
|
2021
Q1 | $713K | Buy |
23
+16
| +229% | +$586K | ﹤0.01% | 3688 |
|
|
2020
Q4 | $234K | Buy |
7
+2
| +40% | +$71K | ﹤0.01% | 3837 |
|
|
2020
Q3 | $193K | Hold |
5
| – | – | ﹤0.01% | 3732 |
|
|
2020
Q2 | $219K | Buy |
5
+2
| +67% | +$94.8K | ﹤0.01% | 3639 |
|
|
2020
Q1 | $77K | Hold |
3
| – | – | ﹤0.01% | 3839 |
|
|
2019
Q4 | $115K | Hold |
3
| – | – | ﹤0.01% | 3956 |
|
|
2019
Q3 | $140K | Hold |
3
| – | – | ﹤0.01% | 3879 |
|
|
2019
Q2 | $158K | Hold |
3
| – | – | ﹤0.01% | 3850 |
|
|
2019
Q1 | $102K | Hold |
3
| – | – | ﹤0.01% | 3892 |
|
|
2018
Q4 | $131K | Hold |
3
| – | – | ﹤0.01% | 3806 |
|
|
2018
Q3 | $202K | Hold |
3
| – | – | ﹤0.01% | 3766 |
|
|
2018
Q2 | $226K | Buy |
3
+1
| +50% | +$81.9K | ﹤0.01% | 3685 |
|
|
2018
Q1 | $154K | Hold |
2
| – | – | ﹤0.01% | 3755 |
|
|
2017
Q4 | $159K | Buy |
2
+1
| +100% | +$86.5K | ﹤0.01% | 3728 |
|
|
2017
Q3 | $140K | Hold |
1
| – | – | ﹤0.01% | 3746 |
|
|
2017
Q2 | $110K | Buy |
+1
| New | +$43.5K | ﹤0.01% | 3826 |
|
Other funds holding MBRX
Geode Capital Management's MBRX Position: Q2 2026 in Review
Geode Capital Management increased its Moleculin Biotech (MBRX) stake by 46% in Q2 2026, buying an estimated $38.1K and bringing the position to 2,363 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #4039.
Geode Capital Management first reported a position in MBRX in Q2 2017 and has held it in 37 quarters since. The position peaked at $871K in Q2 2021. 15 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.
- Geode Capital Management held 2,363 shares of Moleculin Biotech worth $132K as of Q2 2026.
- Geode Capital Management bought 747 Moleculin Biotech shares in Q2 2026, an estimated $38.1K.
- Moleculin Biotech made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4039 holding.
- Geode Capital Management first reported a position in Moleculin Biotech in Q2 2017 and has held it in 37 quarters since.
- Geode Capital Management's Moleculin Biotech position peaked at $871K in Q2 2021.
- 15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.